tiprankstipranks
Analyst Profile
Followed by 200 other investors
.
Matthew Taylor

Matthew Taylor

UBS
Wall Street Analyst
Ranked #355 out of 8,047 Analysts on TipRanks (#474 out of 21,521 overall experts)

Success Rate

63%
190 out of 301 Profitable Transactions

Average Return

12.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Matthew Taylor's ratings since 2014 and opened each position for the duration of 1 Year:
63.12% of your transactions would have been profitable with an average return of 12.6%

Stock Rating Distribution

523Ratings
56.60% Buy
35.56% Hold
7.84% Sell
Distribution of Matthew Taylor's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Inmode
(INMD)
Rating Type:Buy
Dates:Nov 13, 2020 - Nov 13, 2021
Gain:346.10%
The most profitable rating made by Matthew Taylor

Matthew Taylor's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
LipoScience
Buy
Assigned
50%
-4.70%
2
Carefusion Corp
Hold
Assigned
0.00%
6
Covidien
Hold
Downgraded
0.00%
1
Hospira Inc
Hold
Assigned
0%
-35.85%
6
Thoratec Corp
Hold
Reiterated
0%
-19.95%
4
Baxalta Incorporated
Hold
Reiterated
0.00%
1
Lombard Medical
Hold
Reiterated
$2.50
(249999900.00% Upside)
0.00%
2
LDR Holding
Hold
Downgraded
100%
+75.60%
2
St Jude Medical
Hold
Reiterated
91%
+14.94%
15
HeartWare International
Hold
Reiterated
25%
-4.50%
6
List of latest recommendations made by Matthew Taylor. Click to expand and see Matthew Taylor's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More